158 related articles for article (PubMed ID: 19355879)
1. Naphthalimides and azonafides as promising anti-cancer agents.
Ingrassia L; Lefranc F; Kiss R; Mijatovic T
Curr Med Chem; 2009; 16(10):1192-213. PubMed ID: 19355879
[TBL] [Abstract][Full Text] [Related]
2. Naphthalimide derivatives with therapeutic characteristics: a patent review.
Kamal A; Bolla NR; Srikanth PS; Srivastava AK
Expert Opin Ther Pat; 2013 Mar; 23(3):299-317. PubMed ID: 23369185
[TBL] [Abstract][Full Text] [Related]
3. A new class of naphthalimide-based antitumor agents that inhibit topoisomerase II and induce lysosomal membrane permeabilization and apoptosis.
Chen Z; Liang X; Zhang H; Xie H; Liu J; Xu Y; Zhu W; Wang Y; Wang X; Tan S; Kuang D; Qian X
J Med Chem; 2010 Mar; 53(6):2589-600. PubMed ID: 20170164
[TBL] [Abstract][Full Text] [Related]
4. Heterocyclic Naphthalimides as New Skeleton Structure of Compounds with Increasingly Expanding Relational Medicinal Applications.
Gong HH; Addla D; Lv JS; Zhou CH
Curr Top Med Chem; 2016; 16(28):3303-3364. PubMed ID: 27150364
[TBL] [Abstract][Full Text] [Related]
5. Research Progress on Structure-Activity Relationship of 1,8-Naphthalimide DNA Chimeras Against Tumor.
Zhang HY; Han LL; Wu HY; Xu XX; Yu MB; Chen GY; Qi XL
Technol Cancer Res Treat; 2024; 23():15330338231225861. PubMed ID: 38225189
[TBL] [Abstract][Full Text] [Related]
6. Overview of naphthalimide analogs as anticancer agents.
Lv M; Xu H
Curr Med Chem; 2009; 16(36):4797-813. PubMed ID: 19929786
[TBL] [Abstract][Full Text] [Related]
7. Preclinical antitumor activity of the azonafide series of anthracene-based DNA intercalators.
Dorr RT; Liddil JD; Sami SM; Remers W; Hersh EM; Alberts DS
Anticancer Drugs; 2001 Mar; 12(3):213-20. PubMed ID: 11290869
[TBL] [Abstract][Full Text] [Related]
8. Oxo-heterocyclic fused naphthalimides as antitumor agents: synthesis and biological evaluation.
Tan S; Yin H; Chen Z; Qian X; Xu Y
Eur J Med Chem; 2013 Apr; 62():130-8. PubMed ID: 23353750
[TBL] [Abstract][Full Text] [Related]
9. Molecular design, chemical synthesis, and biological evaluation of '4-1' pentacyclic aryl/heteroaryl-imidazonaphthalimides.
Li F; Cui J; Guo L; Qian X; Ren W; Wang K; Liu F
Bioorg Med Chem; 2007 Aug; 15(15):5114-21. PubMed ID: 17532640
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of novel C4-benzazole naphthalimide derivatives with potent anti-tumor properties against murine melanoma.
Lu YT; Chen TL; Chang KS; Chang CM; Wei TY; Liu JW; Hsiao CA; Shih TL
Bioorg Med Chem; 2017 Jan; 25(2):789-794. PubMed ID: 27939348
[TBL] [Abstract][Full Text] [Related]
11. 5-Non-amino aromatic substituted naphthalimides as potential antitumor agents: Synthesis via Suzuki reaction, antiproliferative activity, and DNA-binding behavior.
Xie L; Cui J; Qian X; Xu Y; Liu J; Xu R
Bioorg Med Chem; 2011 Jan; 19(2):961-7. PubMed ID: 21208805
[TBL] [Abstract][Full Text] [Related]
12. Naphthalimides as anti-cancer agents: synthesis and biological activity.
Braña MF; Ramos A
Curr Med Chem Anticancer Agents; 2001 Nov; 1(3):237-55. PubMed ID: 12678756
[TBL] [Abstract][Full Text] [Related]
13. The novel anti-tumor agents of 4-triazol-1,8-naphthalimides: synthesis, cytotoxicity, DNA intercalation and photocleavage.
Li X; Lin Y; Wang Q; Yuan Y; Zhang H; Qian X
Eur J Med Chem; 2011 Apr; 46(4):1274-9. PubMed ID: 21345546
[TBL] [Abstract][Full Text] [Related]
14. Novel naphthalimide-amino acid conjugates with flexible leucine moiety as side chain: design, synthesis and potential antitumor activity.
Wu A; Xu Y; Qian X
Bioorg Med Chem; 2009 Jan; 17(2):592-9. PubMed ID: 19109022
[TBL] [Abstract][Full Text] [Related]
15. Unprecedented synthesis, in vitro and in vivo anti-cancer evaluation of novel triazolonaphthalimide derivatives.
Li S; Zhong W; Li Z; Meng X
Eur J Med Chem; 2012 Jan; 47(1):546-52. PubMed ID: 22138307
[TBL] [Abstract][Full Text] [Related]
16. Recent developments on 1,8-Naphthalimide moiety as potential target for anticancer agents.
Tandon R; Luxami V; Tandon N; Paul K
Bioorg Chem; 2022 Apr; 121():105677. PubMed ID: 35202852
[TBL] [Abstract][Full Text] [Related]
17. Novel naphthalimide-benzoic acid conjugates as potential apoptosis-inducing agents: design, synthesis, and biological activity.
Wu A; Mei P; Xu Y; Qian X
Chem Biol Drug Des; 2011 Dec; 78(6):941-7. PubMed ID: 21958160
[TBL] [Abstract][Full Text] [Related]
18. Naphthalimides exhibit in vitro antiproliferative and antiangiogenic activities by inhibiting both topoisomerase II (topo II) and receptor tyrosine kinases (RTKs).
Wang X; Chen Z; Tong L; Tan S; Zhou W; Peng T; Han K; Ding J; Xie H; Xu Y
Eur J Med Chem; 2013 Jul; 65():477-86. PubMed ID: 23770449
[TBL] [Abstract][Full Text] [Related]
19. Analogues of amonafide and azonafide with novel ring systems.
Sami SM; Dorr RT; Alberts DS; Sólyom AM; Remers WA
J Med Chem; 2000 Aug; 43(16):3067-73. PubMed ID: 10956214
[TBL] [Abstract][Full Text] [Related]
20. Fluorescent organometallic rhodium(I) and ruthenium(II) metallodrugs with 4-ethylthio-1,8-naphthalimide ligands: Antiproliferative effects, cellular uptake and DNA-interaction.
Streciwilk W; Terenzi A; Cheng X; Hager L; Dabiri Y; Prochnow P; Bandow JE; Wölfl S; Keppler BK; Ott I
Eur J Med Chem; 2018 Aug; 156():148-161. PubMed ID: 30006161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
